At Delee, we aim to radically change the way cancer is detected, monitored and treated. Through the development of the CytoCatchâ˘, which is a highly sensitive automated benchtop device, we have made possible to rapidly isolate and efficiently analyze circulating tumor cells from blood samples. This innovative technology enables not only the early detection of cancer, but also the continuous monitoring of the diseaseâs evolution and the effectiveness of therapies that are being administered; increasing the patientâs chances of defeating cancer.
No articles found.
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients w...
At ACADIA (NASDAQ: ACAD), we share a passion fo...
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pha...
Established in 2007, and headquartered in Wakef...
Bio-Path is a biotechnology company developing targeted therapies for acute myeloi...
Bio-Path is a biotechnology company developing ...
Eclipes Diagnostics develops CANABINOX, a handheld testing device that can accurat...
Eclipes Diagnostics develops CANABINOX, a handh...
Cloud DX creates easy-to-use medical devices and mobile apps that help people get ...
Cloud DX creates easy-to-use medical devices an...
Ambu A/S engages in the development, production, and marketing of diagnostic and l...
Ambu A/S engages in the development, production...
InSitu Biologics is an emerging biotech company focusing on development of AnestaG...
InSitu Biologics is an emerging biotech company...
Join the National Investor Network and get the latest information with your interests in mind.